Sandoz resubmission puts Amgen's Neulasta at further risk of competition

cafead

Administrator
Staff member
  • cafead   Apr 03, 2019 at 09:43: PM
via Nearly three years after the FDA rejected the Novartis unit's biosimilar application, the company is trying again.

article source